MaxCyte, Inc. MXCT 深 滬
等待開盤 03-26 09:30:00 美东时间
0.6896
-0.050
-6.81%
華盛通- 最 高0.7426
- 今 開0.73
- 成交量 195.11万股
- 最 低 0.676
- 昨 收 0.74
- 總市值 7356.24万
- 52周最高 2.955
- 市盈率 靜 --
- 換手率 1.83%
- 52周最低 0.6434
- 委 比 -14.51%
- 總股本 1.07亿
- 歷史最高 17.44
- 量 比 2.30
- 振 幅 9.00%
- 歷史最低 0.6434
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
今天 11:41
Craig-Hallum Maintains Buy on MaxCyte, Lowers Price Target to $5
Craig-Hallum analyst Matt Hewitt maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $7 to $5.
今天 00:24
电话会总结 ｜ MaxCyte(MXCT)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据MaxCyte业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年全年总营收3,300万美元，同比下降15%（2024年为3,860万美元） - 核心营收2,960万美元，同比下降9%（2024年为3,250万美元） - SPL项目相关营收340万美元，大幅下降44%（2024年为610万美元） - Q4单季度总营收730万美元，同比下降16%（2024年Q4为870万美元） **营收构成细分：** - 仪器营收：全年680万美元 vs 2024年710万美元 - 许可营收：全年890万美元 vs 202
03-25 12:06
MaxCyte Sees FY2026 Sales $30.000M-$32.000M vs $38.405M Est
MaxCyte (NASDAQ:MXCT) sees FY2026 sales of $30.000 million-$32.000 million vs $38.405 million analyst estimate.
03-25 04:06
MaxCyte Q4 EPS $(0.09), Inline, Sales $7.300M Miss $9.398M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company
03-25 04:05
Earnings Scheduled For March 24, 2026
Companies Reporting Before The Bell • Fennec Pharmaceuticals (NASDAQ:FENC) is e...
03-24 19:11
MaxCyte Reports Q4 Revenue Around $6.7M Vs $9.3M Est, Full-Year Revenue Near $30M Vs $35.41M Est
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell
01-12 21:18
MaxCyte CFO Douglas Swirsky To Transition From Role In H1 2026
MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
2025-11-13 05:17
MaxCyte Q3 EPS $(0.12) Misses $(0.11) Estimate, Sales $6.829M Miss $8.370M Estimate
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same
2025-11-13 05:09
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
2025-11-12 19:11
